>Marché du traitement du glioblastome multiforme au Moyen-Orient et en Afrique, par type (primaire (de novo), secondaire), traitement (chirurgie, radiothérapie , médicaments), type de patient ( adultegériatrique , enfant), type de médicament (génériques, de marque), voie d'administration (parentérale, orale, autres), utilisateur final (hôpitaux, cliniques, soins à domicile, autres), canal de distribution (pharmacie hospitalière, pharmacie de détail, pharmacie en ligne, autres) Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché
Le glioblastome multiforme (GBM) est une tumeur maligne de grade IV de l'OMS avec différenciation astrocytaire. En tant que l'une des tumeurs oncologiques du système nerveux central (SNC) les plus fréquemment diagnostiquées cliniquement, il existe une grande variété de rapports historiques sur la description et l'évolution des idées concernant ces tumeurs. Les premiers rapports enregistrés sur les gliomes ont été donnés dans des rapports scientifiques britanniques, par Berns en 1800 et en 1804 par Abernety, la première description histomorphologique complète étant donnée en 1865 par Rudolf Virchow. En 1926, Percival Bailey et Harvey Cushing ont donné la base de la classification moderne des gliomes. Entre 1934 et 1941, le chercheur le plus prolifique dans la recherche sur les gliomes était Hans-Joachim Scherer, qui a postulé certains des aspects clinico-morphologiques du GBM. Avec l'introduction des tests moléculaires et génétiques, la véritable multiformité du GBM a été établie, avec différents génotypes présentant la même image histomorphologique et IHC, ainsi que certains aspects de la gliomagénèse. Pour qu'un GBM se développe, une mutation de déclenchement spécifique doit se produire dans une cellule souche du GBM - GBM primaire, ou une agrégation lente de mutations individuelles, sans mutation de déclenchement distincte - GBM secondaire. La connaissance du GBM est étroitement liée aux connaissances médicales générales du SNC depuis que ces tumeurs malignes ont été décrites pour la première fois il y a plus de 200 ans. Plusieurs grands progrès ont été réalisés au cours de cette période, dans les traces du SNC et des progrès des connaissances médicales générales. La demande de traitement du glioblastome multiforme augmente, pour laquelle les fabricants sont impliqués dans le lancement de nouveaux produits, l'augmentation des produits en cours de développement et la participation aux événements sur le marché. Ces décisions favorisent en fin de compte la croissance du marché.
Le rapport sur le marché du traitement du glioblastome multiforme fournit des détails sur la part de marché, les nouveaux développements, l’impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché, les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l’analyse et le scénario du marché, contactez-nous pour un briefing d’analyste, notre équipe vous aidera à créer une solution d’impact sur les revenus pour atteindre votre objectif souhaité. Les initiatives stratégiques telles que la collaboration, l’accord et la signature d’accords de vente pour inventer et innover dans les traitements pharmacologiques sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
Le marché du traitement du glioblastome multiforme est favorable et vise à réduire la progression de la maladie. Data Bridge Market Research analyse que le marché du traitement du glioblastome multiforme connaîtra un TCAC de 5,9 % au cours de la période de prévision de 2022 à 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (personnalisable de 2019 à 2014) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, prix en USD |
|
Segments couverts |
Par type (primaire (de novo), secondaire), traitement (chirurgie, radiothérapie, médicaments), type de patient (adulte, gériatrique, enfant), type de médicament (générique, de marque), voie d'administration (parentérale, orale, autres), utilisateur final (hôpitaux, cliniques, soins à domicile, autres), canal de distribution (pharmacie hospitalière, pharmacie de détail, pharmacie en ligne, autres) |
|
Pays couverts |
Afrique du Sud, Égypte, Israël, Émirats arabes unis, reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
Français F. Hoffmann-La Roche AG, Amgen Inc., Merck & Co., Inc., Pfizer Inc., Varian Medical Systems, Inc. (une filiale de Siemens Healthcare), ZEISS International, Amneal Pharmaceuticals LLC, Elekta, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Eckert & Ziegler, Accord Healthcare, Angiochem, ANI Pharmaceuticals, Inc., Arbor Pharmaceuticals, LLC. (une filiale d'Azurity Pharmaceuticals, Inc.), AstraZeneca, Cantex Pharmaceuticals, Inc., CELON LABS, Diffusion Pharmaceuticals Inc., EnGeneIC, ERC.SA., Genenta science, Jazz Pharmaceuticals, Inc., Loxo Oncology (une filiale d'Eli Lilly), Novartis AG, VBL THERAPEUTICS, Viatris Inc. et Zydus Pharmaceuticals, Inc., entre autres. |
Définition du marché
Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor and accounts for 60% of brain tumors in adults. GBMs can arise in the brain de novo or evolve from lower-grade astrocytoma. In adults, GBM occurs most often in the cerebral hemispheres, especially in the frontal and temporal lobes of the brain. Many genetic and environmental factors have been studied in glioblastoma multiforme, but no risk factor that accounts for a large proportion of GBM has been identified. So like many other cancers, GBM is sporadic, although some studies indicate a high prevalence (17%) of prior therapeutic irradiation among patients with GBM. The latency between irradiation and the development of GBM varies from a few years to several decades. There is no substantial evidence of GBM association with lifestyle factors like smoking, alcohol consumption, drug use, or exposure to N- Nitroso compounds. Studies have shown that the use of mobile phones doesn't increase the risk of development of GBM; however, its association with long term use needs further confirmation.
Glioblastoma Multiforme Treatment Market Dynamics
Drivers
- Growing prevalence of glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most commonly occurring malignant primary brain tumor, representing 77%-81% of all central nervous system (CNS) primary malignant tumors. The World Health Organization classified it as a grade IV diffuse astrocytic and oligodendroglial tumor. The mean age of primary GBM presentation is 62 years, and the median survival is approximately 14.6 months. The poor prognosis associated with GBM is well documented, while survival rates remain disappointingly low despite medical and surgical advances. As per the study, International studies reveal an approximate annual incidence rate of 0.59 to 5 per 100,000 persons; however, studies indicate a rise in incidence. Miranda-Filho et al. in 2017 described increasing rates of CNS and brain cancers in countries in South America, Eastern Europe, and Southern Europe, while decreasing rates were only reported in Japan. Dobes et al. in 2011 have also noted an increasing incidence of GBM tumors in two of their multicentered Australian studies, with a particular increase in frontal and temporal lobe GBM tumors. The increased incidence of glioblastoma multiforme raises the demand for early detection and diagnosis via utilizing the latest technology, propelling the global glioblastoma multiforme treatment market. The rising incidence of glioblastoma across the globe is expected to accelerate the demand for glioblastoma multiforme treatment. Thus, the increased incidence rates of glioblastoma multiforme are expected to boost the market's growth.
- Increasing research and development (r&d)
Increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side effects of the existing treatment methods, thus creating broader acceptance amongst patients. Tumor heterogeneity and variation in the patient-to-patient treatment approach are expected to increase the demand for a personalized treatment approach to manage glioblastoma multiforme. The approval of new treatments is expected to increase the life expectancy of patients living with glioblastoma multiforme. Furthermore, a special designation granted to investigational drugs by the FDA is expected to expedite novel therapy's approval process and commercialization. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme. The increasing approval for novel therapy and combination therapy is expected to drive theglioblastoma multiforme treatment market.
Opportunity
- Increasing drug approvals
The escalating demand for glioblastoma multiforme treatment should yield more regulatory approvals for associated drugs. Increasing regulatory endorsements for related drugs and recombinant products will constitute an increase in glioblastoma multiforme treatment market value in the coming years. In the framework of a Pan American Health Organization (PAHO) initiative to promote the recognition of Drug Regulatory Authorities, ANMAT´s evaluation process finished on December 11, 2009. The glioblastoma multiforme treatment industry has witnessed numerous drug approvals in recent years, driven by the increasing fatality rate of the disease. Increasing drug approvals will ramp up the glioblastoma multiforme treatment market demand.
Restraints/Challenges
High cost of glioblastoma multiforme treatment
The diagnostic tests for glioblastoma multiforme include highly technologically advanced products. Developing those products involves rigorous research and development by the developing player. Thus, the cost of the product remains high, which proportionally increases the cost of testing.
The diagnostic tools and techniques used for the diagnosis of glioblastoma multiforme include
radiation therapy, chemotherapy, among others. Early stages of GBM typically present with minimal or no symptoms; therefore, GBM is frequently diagnosed at advanced stages, resulting in a poor prognosis. Thus, the high cost of treating the glioblastoma multiforme using the advanced modalities and technology products will act as a major restraining factor for the growth of the global glioblastoma multiforme treatment market.
Recent Developments
- In April 2022, Elekta and GE Healthcare announced that they had signed a global commercial collaboration agreement in the field of radiation oncology, enabling them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy. This partnership will allow the companies to jointly promote solutions for each cancer center’s needs
- In July 2019, Amgen and Allergan plc announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) is available in the United States (U.S.). This launch will enhance the sales of the product in the region
Glioblastoma Multiforme Treatment Market Scope
The glioblastoma multiforme treatment market is categorized into seven notable segments which are based on type, treatment, patient type, drug type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Primary (De Novo)
- Secondary
On the basis of type, the glioblastoma multiforme treatment market is segmented into primary (De Novo) and secondary.
Treatment
- Surgery
- Radiotherapy
- Medications
On the basis of treatment, the glioblastoma multiforme treatment market is segmented into surgery, radiotherapy and medications .
Patient Type
- Adult
- Geriatric
- Child
On the basis of patient type, the glioblastoma multiforme treatment market is segmented into adult, geriatric and child.
Drug Type
- Branded
- Generics
On the basis of drug type, the glioblastoma multiforme treatment market is segmented into generics and branded.
Route of Administration
- Oral
- Parenteral
- Others
On the basis of route of administration, the glioblastoma multiforme treatment market is segmented into parenteral, oral and others.
End User
- Hospitals
- Clinics
- Home Healthcare
- Others
On the basis of end user, the glioblastoma multiforme treatment market is segmented into hospitals, clinics, home healthcare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the glioblastoma multiforme treatment market is segmented into hospital pharmacy, retail pharmacy and others.
Glioblastoma Multiforme Treatment Market Regional Analysis/Insights
The glioblastoma multiforme treatment market is analysed and market size insights and trends are provided by type, treatment, patient type, drug type, route of administration, end user and distribution channel as referenced above.
The regions covered in the glioblastoma multiforme treatment market report are U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa.
South Africa is expected to dominate the market due to the increased awareness about the disease in the country.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Glioblastoma Multiforme Treatment Market Share Analysis
The glioblastoma multiforme treatment market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on glioblastoma multiforme treatment market.
Some of the key players in the market are F. Hoffmann-La Roche AG, Amgen Inc., Merck & Co., Inc., Pfizer Inc., Varian Medical Systems, Inc. (A subsidiary of Siemens Healthcare), ZEISS International, Amneal Pharmaceuticals LLC, Elekta, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Eckert & Ziegler, Accord Healthcare, Angiochem, ANI Pharmaceuticals, Inc., Arbor Pharmaceuticals, LLC. (A Subsidiary of Azurity Pharmaceuticals, Inc.), AstraZeneca, Cantex Pharmaceuticals, Inc., CELON LABS, Diffusion Pharmaceuticals Inc., EnGeneIC, ERC.SA., Genenta science, Jazz Pharmaceuticals, Inc., Loxo Oncology (A Subsidiary of Eli Lilly), Novartis AG, VBL THERAPEUTICS, Viatris Inc., and Zydus Pharmaceuticals, Inc., among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global Vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: REGULATORY SCENARIO
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROWING PREVALENCE OF GLIOBLASTOMA MULTIFORME
8.1.2 INCREASING RESEARCH AND DEVELOPMENT (R&D)
8.1.3 PRESENCE OF A STRONG PIPELINE
8.1.4 GROWING GERIATRIC POPULATION
8.2 RESTRAINTS
8.2.1 HIGH COST OF GLIOBLASTOMA MULTIFORME TREATMENT
8.2.2 ADVERSE SIDE-EFFECTS OF GLIOBLASTOMA MULTIFORME TREATMENT
8.3 OPPORTUNITIES
8.3.1 INCREASING DRUG APPROVALS
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT
8.4 CHALLENGES
8.4.1 LACK OF NEW TREATMENT
8.4.2 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS
8.4.3 LACK OF EARLY DETECTION
9 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE
9.1 OVERVIEW
9.2 PRIMARY (DE NOVO)
9.3 SECONDARY
10 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 SURGERY
10.3 RADIOTHERAPY
10.3.1 BRACHYTHERAPY
10.3.2 FRACTIONATED STEREOTACTIC RT (FSRT)
10.3.3 CONFORMAL OR INTENSITY-MODULATED RT
10.3.4 RADIOSURGERY
10.4 MEDICATIONS
10.4.1 TEMOZOLOMIDE
10.4.1.1 ORAL
10.4.1.1 INTRAVENOUS
10.4.2 NITROSOUREAS DRUGS
10.4.2.1 CARMUSTINE
10.4.2.1.1 PARENTERAL
10.4.2.1.2 IMPLANTABLE WAFERS
10.4.2.2 LOMUSTINE
10.4.2.3 NIMUSTINE
10.4.2.4 FOTEMUSTINE
10.4.3 TARGETED THERAPY
10.4.3.1 BEVACIZUMAB
10.4.3.2 OTHERS
10.4.4 ANTI-EPILEPTICS
10.4.4.1 LEVETIRACETAM
10.4.4.2 PHENYTOIN
10.4.4.3 CARBAMAZEPINE
10.4.5 CORTICOSTEROIDS
10.4.5.1 METHYLPREDNISOLONE
10.4.5.2 PREDNISONE
10.4.5.3 OTHERS
11 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE
11.1 OVERVIEW
11.2 ADULT
11.2.1 MALE
11.2.2 FEMALE
11.3 GERIATRIC
11.3.1 MALE
11.3.2 FEMALE
11.4 CHILD
12 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERICS
12.3 BRANDED
13 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 PARENTERAL
13.3 ORAL
13.3.1 CAPSULES
13.3.2 TABLETS
13.3.3 POWDERS
13.4 OTHERS
14 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL
14.3 CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACY
15.5 OTHERS
16 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION
16.1 MIDDLE EAST & AFRICA
16.1.1 SOUTH AFRICA
16.1.2 U.A.E.
16.1.3 EGYPT
16.1.4 ISRAEL
16.1.5 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 F.HOFFMAN-LA ROCHE
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 AMGEN INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.2.5.1 PRODUCT APPROVAL
19.3 MERCK & CO., INC
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.3.5.1 STRATETIC COLLABORATION
19.3.5.2 EVENTS
19.4 PFIZER INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.4.5.1 MERGER
19.5 VARIAN MEDICAL SYSTEMS, INC. (A SUBSIDIARY OF SIEMENS HEALTHCARE)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.5.5.1 PARTNERSHIP
19.5.5.2 ACQUISITION
19.6 ZEISS INTERNATIONAL
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.6.4.1 PRODUCT EXPANSION
19.7 AMNEAL PHARMACEUTICALS LLC
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.7.4.1 EVENT
19.7.4.2 LAUNCH
19.7.4.3 ACQUISITION
19.8 ELEKTA
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.8.4.1 PARTNERSHIP
19.9 SUN PHARMACEUTICAL INDUSTRIES LTD
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.9.4.1 AGREEMENT
19.1 TEVA PHARMACEUTICAL INDUSTRIES LTD
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 ECKERT & ZIEGLER
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 ACCORD HEALTHCARE
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 ANGIOCHEM
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.13.3.1 AGREMEENT
19.14 ANI PHARMACEUTICALS, INC.
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.14.4.1 ACQUISITION
19.15 ARBOR PHARMACEUTICALS, LLC. A SUBSIDIARY OF AZURITY PHARMACEUTICALS, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.15.3.1 ACQUISITION
19.15.3.2 PRODUCT APPROVAL
19.16 ASTRAZENECA
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.16.4.1 AGREEMENT
19.17 CANTEX PHARMACEUTICALS, INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 CELON LABS
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 DIFFUSION PHARMACEUTICAL
19.19.1 COMPANY SNAPSHOT
19.19.2 SERVICES PORTFOLIO
19.19.3 RECENT DEVELOPMENT
19.2 ERC.SA
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
19.20.3.1 PIPELINE UPDATE
19.21 ENGENEIC
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENTS
19.21.3.1 AWARDS
19.22 GENENTA SCIENCE
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENT
19.22.3.1 EVENT
19.23 JAZZ PHARMACEUTICALS, INC.
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENT
19.23.4.1 ACQUISITION
19.24 LOXO ONCOLOGY (A SUBSIDIARY OF ELI LILLY)
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 NOVARTIS AG
19.25.1 COMPANY SNAPSHOT
19.25.2 REVENUE ANALYSIS
19.25.3 PRODUCT PORTFOLIO
19.25.4 RECENT DEVELOPMENT
19.26 VBL THERAPEUTICS
19.26.1 COMPANY SNAPSHOT
19.26.2 PRODUCT PORTFOLIO
19.26.3 RECENT DEVELOPMENT
19.26.3.1 EVENT
19.26.3.2 AWARD
19.27 VIATRIS INC
19.27.1 COMPANY SNAPSHOT
19.27.2 REVENUE ANALYSIS
19.27.3 PRODUCT PORTFOLIO
19.27.4 RECENT DEVELOPMENT
19.27.4.1 AGREEMENT
19.28 ZYDUS PHARMACEUTICALS, INC.
19.28.1 COMPANY SNAPSHOT
19.28.2 PRODUCT PORTFOLIO
19.28.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 PIPELINE ANALYSIS FOR GLIOBLASTOMA MULTIFORME TREATMENT MARKET
TABLE 2 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA PRIMARY (DE NOVO) IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA SECONDARY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA SURGERY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA ADULTS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA CHILD IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA GENERICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA BRANDED IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA PARENTERAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA HOSPITAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA CLINICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA HOME HEALTHCARE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA RETAIL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA ONLINE PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA ANTI-EPILEPTIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 62 SOUTH AFRICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 63 SOUTH AFRICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 64 SOUTH AFRICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 65 SOUTH AFRICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 66 SOUTH AFRICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 67 SOUTH AFRICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 68 SOUTH AFRICA ANTI-EPILEPTIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 69 SOUTH AFRICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 70 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 71 SOUTH AFRICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 72 SOUTH AFRICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 73 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 74 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 75 SOUTH AFRICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 76 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 77 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 80 U.A.E. RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 81 U.A.E. MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 82 U.A.E. TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 83 U.A.E. NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 84 U.A.E. CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 85 U.A.E. TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 86 U.A.E. ANTI-EPILEPTIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 87 U.A.E. CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 88 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 89 U.A.E. ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 90 U.A.E. GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 91 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 92 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 93 U.A.E. ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 94 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 95 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 96 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 98 EGYPT RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 99 EGYPT MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 100 EGYPT TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 101 EGYPT NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 102 EGYPT CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 103 EGYPT TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 104 EGYPT ANTI-EPILEPTIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 105 EGYPT CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 106 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 107 EGYPT ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 108 EGYPT GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 109 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 110 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 111 EGYPT ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 112 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 113 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 114 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 116 ISRAEL RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 117 ISRAEL MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 118 ISRAEL TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 119 ISRAEL NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 120 ISRAEL CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 121 ISRAEL TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 122 ISRAEL ANTI-EPILEPTIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 123 ISRAEL CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 124 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 125 ISRAEL ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 126 ISRAEL GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 127 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 128 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 129 ISRAEL ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 130 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 131 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 132 REST OF MIDDLE EAST AND AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF GLIOBLASTOMA MULTIFORME AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 PRIMARY (DE NOVO) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET
FIGURE 16 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2021
FIGURE 17 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2021
FIGURE 21 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2022-2029 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, CAGR (2022-2029)
FIGURE 23 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2021
FIGURE 25 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 27 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2021
FIGURE 29 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 31 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 33 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 34 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 35 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2021
FIGURE 37 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 38 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 42 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 45 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 46 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022 & 2029)
FIGURE 49 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
